BioCentury | Aug 3, 2015
Company News

Hemostemix, Ludwig Boltzmann Institute deal

...Hemostemix and Ludwig Boltzmann Institute (LBI) partnered to evaluate Hemostemix’s ACP-01 to restore blood supply. The partnership will...
...is in Phase II testing to treat critical limb ischemia. Hemostemix Inc. (TSX-V:HEM), Calgary, Alberta Ludwig Boltzmann Institute for Experimental and Clinical Traumatology...
BioCentury | Nov 5, 2009
Distillery Therapeutics

Indication: Autoimmune disease

...al. Proc. Natl. Acad. Sci. USA; published online Oct. 19, 2009; doi:10.1073/pnas.0910371106 Contact: Lukas Kenner, Ludwig Boltzmann Institute...
BioCentury | Jul 5, 2004
Company News

Halozyme scientific advisory board update

...Halozyme Therapeutics Inc. , San Diego, Calif. Business: Cancer Appointed: Gerhard Baumgartner, professor at the Ludwig Boltzmann Institute...
Items per page:
1 - 3 of 3
BioCentury | Aug 3, 2015
Company News

Hemostemix, Ludwig Boltzmann Institute deal

...Hemostemix and Ludwig Boltzmann Institute (LBI) partnered to evaluate Hemostemix’s ACP-01 to restore blood supply. The partnership will...
...is in Phase II testing to treat critical limb ischemia. Hemostemix Inc. (TSX-V:HEM), Calgary, Alberta Ludwig Boltzmann Institute for Experimental and Clinical Traumatology...
BioCentury | Nov 5, 2009
Distillery Therapeutics

Indication: Autoimmune disease

...al. Proc. Natl. Acad. Sci. USA; published online Oct. 19, 2009; doi:10.1073/pnas.0910371106 Contact: Lukas Kenner, Ludwig Boltzmann Institute...
BioCentury | Jul 5, 2004
Company News

Halozyme scientific advisory board update

...Halozyme Therapeutics Inc. , San Diego, Calif. Business: Cancer Appointed: Gerhard Baumgartner, professor at the Ludwig Boltzmann Institute...
Items per page:
1 - 3 of 3